Abstract:Background: Lung cancer is the most common primary malignant tumor of the lung, and as one of the malignant tumors that pose the greatest threat to the health of the population, the incidence rate has remained high in recent years. Previous studies have shown that KLRB1 is transcriptionally repressed in lung adenocarcinoma and correlates with lung adenocarcinoma prognosis. The objective of this study is to investigate the intrinsic mechanisms by which KLRB1 affects the malignant phenotypes of lung adenocarcinoma such as immune infiltration, proliferation, growth and metastasis. Methods: We assessed the expression levels of KLRB1 in publicly available databases and investigated its associations with clinical and pathological variables. Enrichment analysis was subsequently conducted to investigate possible signaling pathways and their associated biological functions. Statistical analysis, including Spearman correlation and the application of multigene prediction models, was utilized to assess the relationship between the expression of KLRB1 and the infiltration of immune cells. The diagnostic and prognostic value of KLRB1 was evaluated using Kaplan-Meier survival curves, diagnostic receptor operating characteristic (ROC) curves, histogram models, and Cox regression analysis. Specimens from lung adenocarcinoma (LUAD) patients were collected, the expression level of KLRB1 was detected by protein blotting analysis, and the expression level of KLRB1 was detected at the mRNA level by real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR). Small interfering RNA (siRNA) was used to silence gene expression, and Transwell, Cell Counting Kit-8 (CCK-8) and colony formation assays were subsequently performed to analyze the effects of KLRB1 on LUAD cell migration, invasion and proliferation. Results: KLRB1 expression was lower in lung cancer tissue than in surrounding healthy tissue. Genes differentially expressed in the low and high KLRB1 expression groups were found to be significantly enriched in pathways related to immunity. KLRB1 exerted an impact on the MAPK/ERK signaling pathway, thereby modulating the growth and proliferation of LUAD cells. KLRB1 expression is linked to prognosis, immune infiltration, and cell migration and proliferation in LUAD. Conclusions: The evidence revealed a correlation between KLRB1 and both prognosis and immune infiltration in LUAD patients.

Cytoplasmic Liver Kinase B1 Promotes the Growth of Human Lung Adenocarcinoma by Enhancing Autophagy.

Liver Kinase B1 (LKB1) Regulates Proliferation and Apoptosis of Non-Small Cell Lung Cancer A549 Cells via Targeting ERK Signaling Pathway

Tumor Suppressor LKB1 Inhibits the Progression of Gallbladder Carcinoma and Predicts the Prognosis of Patients with This Malignancy

Overexpression of the LKB1 Gene Inhibits Lung Carcinoma Cell Proliferation Partly Through Degradation of C-Myc Protein.

Reduced Expression of Liver Kinase B1 and Beclin1 is Associated with the Poor Survival of Patients with Non-Small Cell Lung Cancer

Under-expression of LKB1 is Associated with Enhanced P38-Mapk Signaling in Human Hepatocellular Carcinoma.

FBXO22 Mediates Polyubiquitination and Inactivation of LKB1 to Promote Lung Cancer Cell Growth

Expression Profiling of Ubiquitin-Related Genes in LKB1 Mutant Lung Adenocarcinoma.

Suppression of Lung Cancer Cell Invasion by LKB1 is Due to the Downregulation of Tissue Factor and Vascular Endothelial Growth Factor, Partly Dependent on SP1

Lamin B1 Overexpresses in Lung Adenocarcinoma and Promotes Proliferation in Lung Cancer Cells Via AKT Pathway.

KLRB1 expression is associated with lung adenocarcinoma prognosis and immune infiltration and regulates lung adenocarcinoma cell proliferation and metastasis through the MAPK/ERK pathway

LKB1 Modulates Lung Cancer Differentiation and Metastasis.

[Effect of transfection of LKB1 on biological behavior of human lung adenocarcinoma cells].

Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α

Clinical significance and role of LKB1 in gastric cancer.

LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer

Lkb1 Inhibits Lung Cancer Progression Through Lysyl Oxidase And Extracellular Matrix Remodeling

LKB 1 / AMPK / Mtor Signaling Pathway in Non-small-cell Lung Cancer

LKB1 and lung cancer: more than the usual suspects

The tumor suppressor LKB1 antagonizes WNT signaling pathway through modulating GSK3β activity in cell growth of esophageal carcinoma

Posttranslational regulation of liver kinase B1 in human cancer